期刊文献+

茴拉西坦/MCM-48载体的制备及释药性能研究

Preparation and drug release performance of aniracetam/MCM-48 materials
下载PDF
导出
摘要 为了提高难溶性药物的口服生物利用度,采用水热合成法制备了MCM-48介孔二氧化硅载体材料,利用浸渍法将水难溶性药物茴拉西坦负载于MCM-48载体上。利用扫描电子显微镜(SEM)、透射电子显微镜(TEM)、激光粒度仪、小角X射线衍射(XRD)、N2吸附-脱附、红外光谱(IR)、差热-热重(DTA-TG)对载药前后MCM-48的表面形貌、粒径、孔径、孔容、比表面积、晶胞参数等进行测试,结果表明,MCM-48外形为球形颗粒,介孔结构为三维立方结构,孔径3.55 nm,孔容及比表面积分别为0.86 cm^3/g和764 m^2/g;MCM-48负载茴拉西坦的载药量为16%,载药后药物以非晶态装载于介孔孔道中或吸附于载体表面,没有影响MCM-48的骨架结构,但使孔径、孔容及比表面积下降。通过在不同pH溶液中载药MCM-48与茴拉西坦原料药的溶出度比较发现,MCM-48载体能够提高茴拉西坦的溶出速率。 In order to improve the oral bioavailability of insoluble drugs,MCM-48 as mesoporous silica carrier was prepared by hydrothermal method.The poorly water-soluble drug Aniracetam was loaded on MCM-48 by dipping method.The surface morphology,particle size,pore size,pore volume,specific surface area and cell parameters of drug unloaded and loaded MCM-48 were investigated by SEM,TEM,laser particle size analyzer,XRD,N2 adsorption-desorption test,IR,DTA-TG.The results showed that MCM-48 with spherical shape was three-dimensional cubic structure with pore size of 3.55 nm,pore volume of 0.86 cm^3/g and specific surface area of 764 m^2/g.The drug loading of MCM-48 was 16%,and the drug with amorphous state loaded in the mesoporous pores or on the surface without any effect on the skeleton structure of MCM-48 which decreased pore size,pore volume and specific surface area.MCM-48 loaded with Aniracetam could enhance its dissolution rate comparing with unloaded Aniracetam in different pH solution.
作者 吕江维 魏亚青 王鹏光 孙晗 张文君 任君刚 王立 Lü Jiang-wei;WEI Ya-qing;WANG Peng-guang;SUN Han;ZHANG Wen-jun;REN Jun-gang;WANG Li(School of Pharmacy,Harbin University of Commerce,Harbin 150076,China)
出处 《应用化工》 CAS CSCD 北大核心 2020年第2期359-363,共5页 Applied Chemical Industry
基金 国家自然科学基金项目(51308171) 哈尔滨商业大学青年创新人才支持项目(2016QN075)。
关键词 介孔二氧化硅 茴拉西坦 MCM-48 mesoporous silica nanoparticles aniracetam MCM-48
  • 相关文献

参考文献4

二级参考文献46

  • 1Ku MS, Dulin W. A biopharmaceutical classification based Right-First-Time formulation approach to reduce human phar- macokinetic variability and project cycle time from First In-Hu- man to clinical Proof-Of Concept [J]. Pharma Dev Technol, 2010, 17(3): 285-302.
  • 2Takagi T, Ramachandran C, Amidon GL, et al. A provisional biopharmaceutical classification of the top 200 oral drug prod ucts in the United States, Great Britain, Spain, and Japan[J]. Mol Pharm, 2006, 3(6): 631-643.
  • 3Amidon GL, Lennernas H, Shah VP, etal. A theoretical ba- sis for a biopharmaeeutie drug classi? cation: the correlation of in vitro drug product dissolution and in vivo bioavailability[J]. Pharm Res, 1995, 12(3):413-420.
  • 4Volpe D A. Variability in Caeo-2 and MI)CK cell based intesti nal permeability assays[J]. J Pharm Sci, 2008, 97 (2) : 712-725.
  • 5Cook J, Addicks W, Wu YH. Application of the biopharma- ceutical classification system in clinical drug development- an industrial view[J]. AAPS J,2008, 10(2) : 3116-310.
  • 6Jung MS, Kim JS, Kim MS, et al. Bioavailability of indom ethacin-saccharin cocrystals[J]. J Pharm Pharmacol, 2010, 62 (11): 1560-1568.
  • 7Bak A, Gore A, Yanez E, et al. The co-crystal approach to improve the exposure of a water-insoluble compound~ AMG 517 sorbic acid co-crystal characterization and pharmacokinetics [J]. J Pharm Sci, 2008, 97(9) : 3942-3956.
  • 8Shegokar R, Muller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble ac- tives[J]. Int J Pharm, 2010, 399(1-2): 129-139.
  • 9Sylvestre JP, Tang MC, Furtos A, et al. Nanonization of megestrol acetate by laser fragmentation in aqueous milieu[J]. J Controlled Rel, 2011, 149(3) : 273-280.
  • 10Vasconeelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs[J]. Drug Dis Today 2007, 12(23-24): 1068-1075.

共引文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部